Beaver Run Resort Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
- Meeting Program
- Meeting Summary
- Abstract Information
- Registration Information
- Scholarships / Awards
- Lodging / Hotels
- Travel / Transportation
- Conference Location
- Things to Do
- Services
- My Account
NOTES:
This meeting will be conducted in English.
All programs are subject to change. Check this site for updates.
Download Flyer
Twitter hashtag for this meeting: #KSpdd
This meeting will be conducted in English.
All programs are subject to change. Check this site for updates.
Download Flyer
Twitter hashtag for this meeting: #KSpdd
Phenotypic Drug Discovery: Recent Advances and Insights from Chemical and Systems Biology (C1)
Scientific Organizers: Mark Mercola, Fabien Vincent, Monica Schenone and Arsenio Nueda
March 3—7, 2019
Beaver Run Resort, Breckenridge, Colorado, USA
Sponsored by Pfizer Inc.
Abstract submission is now closed. Registered attendees may bring a poster onsite. Please contact our office at +1 800-253-0685; +1 970-262-1230 or email info@keystonesymposia.org if you are interested.
BEWARE of booking lodging through companies unaffiliated with Keystone Symposia. Click here for more details.
Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies.
DEADLINES:Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies.
*All deadlines end at 11:59 PM US Mountain Standard Time
Scholarship Deadline: Oct 30, 2018 [details]
Discounted Abstract Deadline: Oct 30, 2018 [details]
Abstract Deadline: Dec 4, 2018 [details]
Discounted Registration Deadline: Jan 11, 2019 [details]
If you have missed a deadline due to the US government shutdown, please contact our office.
Click here to view Cancellation Policy
Discounted Abstract Deadline: October 30, 2018
*All deadlines end at 11:59 PM US Mountain Standard TimeAbstract Submission Fee: 100.00 USD*
Submission by this date receives 50.00 USD discount.
*50.00 USD will be applied to Registration Fee when you register
Abstract Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadlines. Submitting an abstract does not constitute or guarantee registration.
Submitting your abstract early allows us to:
- submit your abstract to organizers to be considered for a short talk
- accept your abstract online
- include your abstract on our website and in our secure mobile app
- reserve your space at the meeting for a poster presentation.**
(The Abstract Deadline: is December 4, 2018)
Global Health Travel Award Deadline:
*All deadlines end at 11:59 PM US Mountain Standard Time
Global Health Travel Award Details:
You MUST complete your Global Health Travel Award appplication by the Global Health Travel Award Deadline
and complete the other required steps (verify your contact information and submit a recommendation letter)
to be considered for a travel award.
Click here to learn more about Global Health Travel Awards.
Scholarship Deadline: October 30, 2018
*All deadlines end at 11:59 PM US Mountain Standard Time
Scholarship Details:
You MUST submit your abstract by the Scholarship Deadline and complete the other required steps (submit a scholarship application and submit a mentor letter) to be considered for a scholarship.
Abstract Deadline: December 4, 2018
*All deadlines end at 11:59 PM US Mountain Standard Time
Abstract Submission Fee: 100.00 USD*
*50.00 USD will be applied to Registration Fee when you register
Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadline. Submitting an abstract does not constitute or guarantee registration.
Submitting your abstract by the Abstract Deadline allows us to:
- submit your abstract to organizers to be considered for a short talk
- include your abstract on our website and in our secure mobile app
- reserve your space at the meeting for a poster presentation.**
Abstracts submitted after the Abstract Deadline will NOT be considered for a short talk.
(Discounted Abstract Deadline: is October 30, 2018)
Discounted Registration Deadline: January 11, 2019
*All deadlines end at 11:59 PM US Mountain Standard Time
Registration Fee: 845.00 USD* (includes 200.00 USD discount)
Student Registration Fee: 620.00 USD* (must complete student verification form)
*Includes 50.00 USD of your abstract submission fee
After the Discounted Registration Deadline:
Registration Fee: 1045.00 USD*
Student Registration Fee: 820.00 USD* (must complete student verification form)
*Includes 50.00 USD of your abstract submission fee
Registration spaces are limited and may fill prior to discounted registration deadline.
Please be advised that some meeting participants have received calls and emails from a number of different housing services,
including "Exhibitors Housing Services," “Expo Housing Services,” "Global Housing," etc. THESE COMPANIES ARE NOT AFFILIATED
WITH KEYSTONE SYMPOSIA and are not authorized by Keystone Symposia to contact you. These companies may tell you that the meeting
is filling, without any actual knowledge to that effect, and pressure you into giving them your credit card number to make a
lodging reservation with them.
We highly recommend that you not make a reservation with these companies or any other housing service! These companies' representations to participants have been misleading. Please report any calls or correspondence you might have received to Keystone Symposia and book only through lodging links in your Keystone Symposia account, an established travel agency or directly with the hotel(s) listed on our website.
We highly recommend that you not make a reservation with these companies or any other housing service! These companies' representations to participants have been misleading. Please report any calls or correspondence you might have received to Keystone Symposia and book only through lodging links in your Keystone Symposia account, an established travel agency or directly with the hotel(s) listed on our website.
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, March 3 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 7 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, March 8 in order to fully experience the meeting.
SUNDAY, MARCH 3
MONDAY, MARCH 4
TUESDAY, MARCH 5
WEDNESDAY, MARCH 6
THURSDAY, MARCH 7
FRIDAY, MARCH 8
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, March 3 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 7 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, March 8 in order to fully experience the meeting.
SUNDAY, MARCH 3
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:15—09:15
Keynote Address
Registered attendees can view abstracts starting on 02/03/2019
Registered attendees can view abstracts starting on 02/03/2019
Big picture view of pharmaceutical development, challenges and new opportunities.
James E. Bradner,
Novartis Institutes for BioMedical Research, USA
PDD, New Approach to Discovering Therapeutics
PDD, New Approach to Discovering Therapeutics
09:15—11:30
Clinical Success Stories
Registered attendees can view abstracts starting on 02/03/2019
Registered attendees can view abstracts starting on 02/03/2019
Share success stories – newly approved drugs and late stage clinical candidates. Identify key lessons and best practices to inform future PDD projects.
Yoshihiro Watanabe,
Kanazawa University, Japan
Discovery of Trametinib as a MEK-Inhibitor Able to Alter Phosphorylation State of MEK
Discovery of Trametinib as a MEK-Inhibitor Able to Alter Phosphorylation State of MEK
Coffee Break
Fred Van Goor,
Vertex Pharmaceuticals Incorporated, USA
Combonation Pharmacology to Treat the Underlying Cause of the Majority of People with Cystic Fibrosis
Combonation Pharmacology to Treat the Underlying Cause of the Majority of People with Cystic Fibrosis
John Tallarico,
Novartis Institutes of Biomedical Research, USA
Novel Therapies from Phenotypic Screening
Novel Therapies from Phenotypic Screening
Herve Tiriac†,
UCSD Heath, USA
Short Talk: Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
Short Talk: Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
14:30—16:30
Workshop 1: Safety De-risking
*
Fabien Vincent,
Pfizer, USA
Short Talks Chosen from Abstracts
17:00—19:00
New Opportunities and Under-Represented Indications
Registered attendees can view abstracts starting on 02/03/2019
Registered attendees can view abstracts starting on 02/03/2019
Illustrate new opportunities for PDD among hard to study and treat diseases. Illustrate new disease modeling technology that can be a breakthrough in finding drug targets and drugs.
Lucienne V. Ronco,
Fulcrum Therapeutics, USA
Talk Title to be Announced
Talk Title to be Announced
Clemens R. Scherzer,
Harvard Medical School, Brigham & Women's Hospital, USA
Turning Bits and Base Pairs into Precision Neurology
Turning Bits and Base Pairs into Precision Neurology
Scott S. Walker,
Merck & Co., Inc., USA
Large-scale Antibacterial Phenotypic Screening and Systematic Hit Triage Reveal Novel Targets and Novel Inhibitors of Established Targets
Large-scale Antibacterial Phenotypic Screening and Systematic Hit Triage Reveal Novel Targets and Novel Inhibitors of Established Targets
Eachan Oliver Johnson,
Broad Institute, USA
Short Talk: Large-Scale Chemical-Genetic Interaction Profiling Yields New Classes of Inhibitors of Mycobacterium tuberculosis
Short Talk: Large-Scale Chemical-Genetic Interaction Profiling Yields New Classes of Inhibitors of Mycobacterium tuberculosis
Patrick W. Faloon,
Biogen, USA
Short Talk: Identification of Small Molecules that Increase Productive Cellular Processing of Antisense Oligonucleotides (ASOs)
Short Talk: Identification of Small Molecules that Increase Productive Cellular Processing of Antisense Oligonucleotides (ASOs)
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
Chemical Biology and Novel Molecular Mechanisms of Action
Registered attendees can view abstracts starting on 02/03/2019
Registered attendees can view abstracts starting on 02/03/2019
Drugging targets considered traditionally undruggable. Small molecule probing of protein conformation/function.
Maurizio Pellecchia,
University of California, Riverside, USA
NMR-based Fragment Screening for Oncology
NMR-based Fragment Screening for Oncology
Laura L. Kiessling,
Massachusetts Institute of Technology, USA
Glycans in Health and Disease
Glycans in Health and Disease
Coffee Break
Razvan L. Cornea,
University of Minnesota, USA
Targeting the Pathological Leak of a Calcium Channel for Heart Failure Therapeutics
Targeting the Pathological Leak of a Calcium Channel for Heart Failure Therapeutics
Monica Schenone,
Pfizer, USA
Talk Title to be Announced
Talk Title to be Announced
Sannah Zoffmann,
F. Hoffmann-La Roche Ltd., Switzerland
Short Talk: Machine Learning-Powered Antibiotics Phenotypic Drug Discovery
Short Talk: Machine Learning-Powered Antibiotics Phenotypic Drug Discovery
Jean-Philippe Coppe,
University of California, San Francisco, USA
Short Talk: Mapping Phospho-Catalytic Dependencies of Therapy-Resistant Tumors Reveals New Actionable Vulnerabilities
Short Talk: Mapping Phospho-Catalytic Dependencies of Therapy-Resistant Tumors Reveals New Actionable Vulnerabilities
Julien Olivet,
Dana-Farber Cancer Institute & Harvard Medical School, USA
Short Talk: Systematic Assessment of Druggable Cavities in a Histone Deacetylase complex
Short Talk: Systematic Assessment of Druggable Cavities in a Histone Deacetylase complex
11:15—12:15
Panel Discussion: Comparing/Contrasting the Practice of PDD
The discussion will cover how PDD is viewed within academia, industry and government organizations (NIH or UK Phenomics Discovery initiative), perhaps covering attitudes, reservations, funding, therapeutic fit, hurdles, what is working, what needs to be improved, etc.
*
Jonathan A. Lee,
PDD4Patients LLC, USA
17:00—19:00
Project Prosecution and Pre-clinical Advancement
Registered attendees can view abstracts starting on 02/03/2019
Registered attendees can view abstracts starting on 02/03/2019
Addressing roadblocks in advancing drugs from phenotypic assays through pre-clinical development. Strategies for selecting high probability leads.
Arsenio Nueda,
Almirall S.A., Spain
Harnessing the Power of Phenotypic Screening to Generate Novel Starting Points for Drug Discovery
Harnessing the Power of Phenotypic Screening to Generate Novel Starting Points for Drug Discovery
Chun-wa Chung,
GlaxoSmithKline, UK
Linking Differential Molecular Mode of Action to Distinct Pharmacology
Linking Differential Molecular Mode of Action to Distinct Pharmacology
Derek Lowe,
Novartis Institutes for Biomedical Research, USA
Advancement of Phenotypic Hits
Advancement of Phenotypic Hits
Short Talk(s) Chosen from Abstracts
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
Physiologically Complex and Realistic Disease Assays
Registered attendees can view abstracts starting on 02/03/2019
Registered attendees can view abstracts starting on 02/03/2019
Incorporating advances in stem cell disease modeling into drug discovery. Technological advances in complex and kinetic readouts. 3D organoids.
Rick Livesey,
University College London, UK
Target Identification and Phenotypic Screening in Stem Cell Models of Neurodegenerative Disease
Target Identification and Phenotypic Screening in Stem Cell Models of Neurodegenerative Disease
Randall T. Peterson,
University of Utah, USA
Zebrafish Behaviors as Phenotypes for Neuroactive Compound Discovery
Zebrafish Behaviors as Phenotypes for Neuroactive Compound Discovery
Coffee Break
Mark Mercola,
Stanford University, USA
High Throughput Kinetic Imaging of iPSC-Derived Cardiomyocytes: Bringing the Patient to the Early Stages of Drug Discovery
High Throughput Kinetic Imaging of iPSC-Derived Cardiomyocytes: Bringing the Patient to the Early Stages of Drug Discovery
Kristin Rockwell,
Pfizer, USA
Short Talk: Functional Genomics Screening in Primary Human T Cells To Identify Novel Targets for Autoimmune Diseases
Short Talk: Functional Genomics Screening in Primary Human T Cells To Identify Novel Targets for Autoimmune Diseases
Alexandre R. Colas,
Sanford-Burnham Medical Research Institute, USA
Short Talk: Novel Single Cell and High-Throughput Phenotypical Platform to Study Atrial Rhythm in hPSCs
Short Talk: Novel Single Cell and High-Throughput Phenotypical Platform to Study Atrial Rhythm in hPSCs
Andrew Snavely†,
Harvard University, USA
Short Talk: A High-Content Phenotypic Screen Against Chemotherapy-Induced Neuropathy Using Human iPSC-Derived Neurons
Short Talk: A High-Content Phenotypic Screen Against Chemotherapy-Induced Neuropathy Using Human iPSC-Derived Neurons
14:30—16:30
Workshop 2: Clinical, Regulatory Case Studies with PDD Project Prosecution
*
Marco Prunotto,
F. Hoffmann-La Roche Ltd., Switzerland
Short Talks Chosen from Abstracts
17:00—19:00
Functional Genomics and Systems Approaches
Registered attendees can view abstracts starting on 02/03/2019
Registered attendees can view abstracts starting on 02/03/2019
Functional genomics, machine learning and data mining.
Anna Greka,
BWH/Harvard Medical School, USA
Toward Targeted, Mechanism-Based Therapies for Kidney Diseases
Toward Targeted, Mechanism-Based Therapies for Kidney Diseases
Lorenz M. Mayr,
GE Healthcare Life Sciences, UK
Phenotypic Drug Discovery - The Move from High Content to High Impact Screening
Phenotypic Drug Discovery - The Move from High Content to High Impact Screening
Giulio Superti-Furga,
Research Center for Molecular Medicine of the Austrian Academy of Sciences, Austria
Systems Pharmacology as an Approach to Network Medicine
Systems Pharmacology as an Approach to Network Medicine
Michael Bassik,
Stanford University, USA
Talk Title to be Announced
Talk Title to be Announced
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—09:00
Benjamin F. Cravatt III,
The Scripps Research, USA
Activity-based Proteomics – Target and Ligand Discovery on a Global Scale
Activity-based Proteomics – Target and Ligand Discovery on a Global Scale
09:00—11:15
Christopher A. Lipinski,
Chrstopher A Lipinski PhD LLC, USA
High Throughput in vivo Phenotypic Screening for Drug Repurposing: Discovery of MLR-1023 a Novel insulin Sensitizer and Novel Lyn Kinase Activator with Clinical Proof of Concept
High Throughput in vivo Phenotypic Screening for Drug Repurposing: Discovery of MLR-1023 a Novel insulin Sensitizer and Novel Lyn Kinase Activator with Clinical Proof of Concept
Coffee Break
Marco Prunotto,
F. Hoffmann-La Roche Ltd., Switzerland
Molecular Phenotyping Combines Molecular Information, Biological Relevance, and Patient Data to Improve Productivity of Early Drug Discovery
Molecular Phenotyping Combines Molecular Information, Biological Relevance, and Patient Data to Improve Productivity of Early Drug Discovery
Umut Ozcan,
Boston Children's Hospital, Harvard Medical School, USA
Withaferin A is a Leptin Sensitizer with Strong Antidiabetic Properties in Mice
Withaferin A is a Leptin Sensitizer with Strong Antidiabetic Properties in Mice
Mo Mandegar,
Tenaya Therapeutics, USA
Short Talk: Artificial Intelligence Accelerates Early Stage Target and Drug Discovery
Short Talk: Artificial Intelligence Accelerates Early Stage Target and Drug Discovery
Christian T. Meyer†,
Vanderbilt University, USA
Short Talk: A Consensus Framework for Calculating Drug Synergy
Short Talk: A Consensus Framework for Calculating Drug Synergy
17:00—18:45
Target Identification / Deconvolution
Registered attendees can view abstracts starting on 02/03/2019
Registered attendees can view abstracts starting on 02/03/2019
Dyann F. Wirth,
Harvard School of Public Health, USA
Target ID for Malaria
Target ID for Malaria
Bridget Wagner,
Broad Institute, USA
The Importance of Phenotypic Screening in Identifying New Targets for Disease Therapeutics
The Importance of Phenotypic Screening in Identifying New Targets for Disease Therapeutics
Herbert Waldmann,
Max Planck Institute for Molecular Physiology, Germany
Chemotype – Phenotype - Target
Chemotype – Phenotype - Target
Heidi Greulich,
Broad Institute, USA
Short Talk: PDE3A Modulation for the Treatment of Cancer
Short Talk: PDE3A Modulation for the Treatment of Cancer
18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Registered attendees can view abstracts starting on 02/03/2019
Registered attendees can view abstracts starting on 02/03/2019
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsor for generously supporting this meeting:
|
|
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Development, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org, Phone:+1 970-262-2676 |
